Semax is a nootropic created by the Institute of Molecular Genetics, Russian Academy of Science. The nootropic was developed within the early 1908s to 1990s and later gained authorization to be marketed to the public . Within Russia, the substance was utilized for treating brain stroke, brain damage after ischemia, optic nerve diseases, and other cognitive disorders. Furthermore, the nootropic has been shown during a private human study to improve cognitive capabilities effectively while positively managing EEG bands .
Enhancement in Cognition
A 2-day clinical study done of Russian power plant employees tested the effectiveness of the nootropic through a number of memory-related tasks. The test lasted for 15 minutes where the first half was done at the start and the other half at the end of employee shift on the first and second day respectively.
A 1 mg dosage was given via the nasal cavity on the first day one hour before testing and the second day shortly after the morning tests were conducted.A placebo group was also asked to conduct the same task.
Semax significantly minimized the number if erroneous responses on the first and last day while the error rate from the placebo group surged. The substance also attenuated a dip in proper performance scores compared to those taking a placebo .
Animal studies done showcased Semax to have the potential for enhancing mood and minimizing anxiety . A recent rat study indicated the nootropic to be capable of minimizing CCK-4 induced depression and stress while not affecting rats given a placebo.
CCK-4 is a powerful neuropeptide that triggers anxiety in animals and human. So much so, the chemicals utilized to trigger panic attacks when scientists are seeking for treatment choices. Such study mostly indicated that rats offered nothing or with Semax was in the same state of mood while rats given CCK-4 were further depressed and anxious on a maze and swim test.
Mixing Semax and CCK-4 back to levels of placebo particular mood parameters, indicate Semax to be capable of treating individuals who are depressed or anxious, while leaving the healthy state as is .
An abstract study done featured within the International Journal of Psychophysiology talked about how Semax, combined with Selank, were capable of triggering sedation effects and relieving certain effects of mental health in animals .
The Semax was found to minimize severe psychotic disturbance times (at 1 to five days) compared to placebo (at 1 to nine days) when given a dosage of 0.6mg daily via inhalation. With subsiding acute symptoms of Semax given at 0.3 mg per day, enhanced cognitive function, and minimal asthenic disorders were observed compared to placebo .
Mechanism of Semax
Within the glial cell structures, both levels of NGF and BDNF increased eight times than normal and gave more after being exposed to Semax. In rats, the nootropic was shown to increase levels of BDNF and trkB levels by up to 1.6 times. Comprehensive research done indicated the nasal intake of Semax promotes an increase in BDNF of rats brains   .
Alpha Brain Wave Activity
Semax was indicated to alter EEG in human cognitive and hyperventilation tests. During the cognitive test, the chemical dramatically decreased the activity of a delta brainwave and enhanced alpha and beta brain rhythm  .
Semax appears to be completely non-toxic and safe. In Russia, the drug is headed under the list of essential and required drugs where it received approval for treating medical conditions such as migraine, stroke, and other cognitive disorders. At the same time, it has comprehensively been tested and included in numerous clinical trials with no reports of hormonal changes or side effects  .